Pain drugs once feared unsafe for gut disease show promise in new review
A new analysis finds that COX-2 inhibitor painkillers—long avoided in inflammatory bowel disease patients—appear safe for short-term use in those with inactive disease. The finding could expand treatment options for millions with IBD who suffer joint and muscle pain, potentially reducing reliance on stronger medications.
Originaltitel: Selective COX-2 inhibitors for short-term musculoskeletal pain in inflammatory bowel disease in remission: a narrative review.
Selektiva COX-2-hämmare kan användas försiktigt vid muskelskeletala smärtor hos IBD-patienter i remission, enligt en ny granskning från Örebro universitet. Två randomiserade placebo-kontrollerade studier visade ingen högre risk för IBD-återfall eller symtomaggrävering under kortvarig behandling, bland annat hos patienter med ulcerös kolit i remission och IBD med reumatiska manifestationer. Öppna studier rapporterade varierande gastrointestinala biverkningar och ibland symtomaggrävering, men studiepopulationerna och uppföljningstiderna skiljde sig väsentligt. Forskare från Örebro universitets medicinska fakultet konstaterar att evidensbasen är begränsad. För praktisk tillämpning rekommenderas tidsbegränsad behandling med lägsta effektiv dos och klinisk övervakning. Resultaten vägleder inköpschefer och chefsläkare vid val av analgetika för denna patientgrupp, där både smärtlindring och tarmsäkerhet måste vägas.
Selective cyclooxygenase-2 (COX-2) inhibitors are often considered when anti-inflammatory analgesia is needed for musculoskeletal pain in patients with inflammatory bowel disease (IBD), but concerns remain about intestinal safety. The clinical evidence on short-term selective COX-2 inhibitor use in IBD, with focus on disease activity outcomes, was reviewed. A prespecified literature search was performed in PubMed and the Cochrane Library supplemented by reference list screening. Clinical trials and clinical studies evaluating celecoxib, etoricoxib or rofecoxib in patients with IBD and musculoskeletal/rheumatological symptoms were considered when gastrointestinal (GI) outcomes were reported. Two placebo-controlled randomised trials did not show higher rates of IBD relapse or symptom aggravation vs placebo during short-term treatment in selected patients, including ulcerative colitis in remission and IBD with rheumatic manifestations. Open-label studies and retrospective series reported variable GI adverse events and occasional symptom worsening, but study populations, baseline disease activity, relapse definitions and follow-up duration differed widely. Overall, the strongest available evidence supports cautious short-term use of selective COX-2 inhibitors in selected patients with IBD in remission when anti-inflammatory analgesia is required. Given the small evidence base and limited follow-up, treatment should be time-limited, use the lowest effective dose and include clinical monitoring.